TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatment Latest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and ...
Biogen Idec Inc. ( BIIB) recently announced that it expects a delay in the EU launch of its oral multiple sclerosis treatment, Tecfidera, as it continues to work on strengthening patent protection for ...
Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...
HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the launch of the first FDA-approved therapeutically equivalent, substitutable generic of ...
CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new data to support the consistent, long-term benefits of treatment with TECFIDERA® (dimethyl fumarate) over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback